DK0617614T3 - Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil - Google Patents

Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil

Info

Publication number: DK0617614T3
Authority: DK; Denmark
Prior art keywords: ligands; retinoid; agents; compounds useful; processes mediated
Prior art date: 1991-12-18

Application number

DK93902758T

Other languages

Danish (da)

English (en)

Inventor

David J Mangelsdorf

Ronald M Evans

Richard A Heyman

Marcus F Boehm

Gregor Eichele

Christina Thaller

Original Assignee

Salk Inst For Biological Studi

Baylor College Medicine

Ligand Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-18

Filing date

1992-12-18

Publication date

1998-09-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25202656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0617614(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-12-18 Application filed by Salk Inst For Biological Studi, Baylor College Medicine, Ligand Pharm Inc filed Critical Salk Inst For Biological Studi

1998-09-28 Application granted granted Critical

1998-09-28 Publication of DK0617614T3 publication Critical patent/DK0617614T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
- C07C403/20—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by carboxyl groups or halides, anhydrides, or (thio)esters thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/26—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/46—Unsaturated compounds containing hydroxy or O-metal groups containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/80—Unsaturated compounds containing keto groups containing rings other than six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6409—Fatty acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
- C12P7/6436—Fatty acid esters
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oil, Petroleum & Natural Gas (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
High Energy & Nuclear Physics (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Cell Biology (AREA)
Immunology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

DK93902758T 1991-12-18 1992-12-18 Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil DK0617614T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80998091A	1991-12-18	1991-12-18
PCT/US1992/011214 WO1993011755A1 (fr)	1991-12-18	1992-12-18	Procedes permettant la modulation de processus utilisant des recepteurs de retinoides comme mediateurs et composes utiles dans ce contexte

Publications (1)

Publication Number	Publication Date
DK0617614T3 true DK0617614T3 (da)	1998-09-28

Family

ID=25202656

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK93902758T DK0617614T3 (da)	1991-12-18	1992-12-18	Midler til modulering af processer medieret af retinoide receptorer og forbindelser anvendlige dertil

Country Status (11)

Country	Link
EP (2)	EP0807624B1 (fr)
JP (2)	JP4001618B2 (fr)
AT (2)	ATE439341T1 (fr)
AU (1)	AU679171B2 (fr)
CA (1)	CA2123223C (fr)
DE (4)	DE617614T1 (fr)
DK (1)	DK0617614T3 (fr)
ES (1)	ES2066750T3 (fr)
LU (1)	LU90752I2 (fr)
NL (1)	NL300043I2 (fr)
WO (1)	WO1993011755A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7056954B2 (en)	1991-12-18	2006-06-06	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US5968989A (en)	1991-12-18	1999-10-19	The Salk Institute For Biological Studies	Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
CZ282548B6 (cs) *	1992-01-22	1997-08-13	F. Hoffmann-La Roche Ag	Farmaceutický přípravek
US5780676A (en) *	1992-04-22	1998-07-14	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5962731A (en) *	1992-04-22	1999-10-05	Ligand Pharmaceuticals Incorporated	Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5466861A (en) *	1992-11-25	1995-11-14	Sri International	Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
ES2129115T3 (es) *	1993-01-11	1999-06-01	Ligand Pharm Inc	Compuestos que tienen actividad selectiva para los receptores de retinoides x, y medios para la modulacion de procesos mediados por receptores de retinoides x.
US5399586A (en) *	1993-03-11	1995-03-21	Allergan, Inc.	Treatment of mammals afflicted with tumors with compounds having RXR retinoid receptor agonist activity
US5585244A (en) *	1994-06-10	1996-12-17	Ligand Pharmaceuticals Incorporated	Detection of retinoid X receptor subtype γ proteins
EP0812354A2 (fr) *	1995-01-23	1997-12-17	Ligand Pharmaceuticals, Inc.	RECEPTEUR $g(g) DE RETINOIDE X HUMAIN (hRXR-GAMMA)
US6942980B1 (en)	1995-09-01	2005-09-13	Allergan, Inc.	Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
EP0788353A1 (fr)	1995-09-18	1997-08-13	Ligand Pharmaceuticals, Inc.	Antagonistes de ppar gamma pour le traitement de l'obesite
US5741896A (en)	1996-06-21	1998-04-21	Allergan	O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity
US5728846A (en)	1996-12-12	1998-03-17	Allergan	Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US5998654A (en) *	1997-07-25	1999-12-07	Ligand Pharmaceuticals Incorporated	Retinoic acid receptor antagonist compounds and methods
CA2334545A1 (fr)	1998-06-12	1999-12-16	Ligand Pharmaceuticals Incorporated	Traitement du cancer du sein resistant aux anti-oestrogenes avec des modulateurs de rxr
US6403638B1 (en)	1998-10-01	2002-06-11	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6048873A (en) *	1998-10-01	2000-04-11	Allergan Sales, Inc.	Tetrahdroquinolin-2-one 6 or 7-yl, tetrahdroquinilin-2-thione 6 or 7-yl pentadienoic acid and related derivatives having retinoid-like biological activity
US6147224A (en) *	1998-10-01	2000-11-14	Allergan Sales, Inc.	2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
FR2787789B1 (fr) *	1998-12-29	2002-06-14	Lipha	Benzopyranes et benzoxepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparations
WO2000061232A2 (fr)	1999-04-14	2000-10-19	Allergan Sales, Inc.	Methodes et compositions destinees au traitement et a la prevention de maladies pulmonaires
WO2000061233A2 (fr)	1999-04-14	2000-10-19	Allergan Sales, Inc.	Methodes et compositions de traitement et de prevention de maladies pulmonaires
US6177588B1 (en)	1999-05-07	2001-01-23	Allergan Sales, Inc.	1-alkoxy and 1-acyloxy substituted cyclohex-1-ene compounds and sulfur and 1-alkoxycarbonyl analogs having retinoid-like biological activity
US6166244A (en)	1999-05-07	2000-12-26	Allergan Sales, Inc.	Oxygen, sulfur and nitrogen substituted cyclohexene and cyclohexane derivatives having retinoid-like biological activity
US6127382A (en) *	1999-08-16	2000-10-03	Allergan Sales, Inc.	Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6093838A (en) *	1999-08-16	2000-07-25	Allergan Sales, Inc.	Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US6313168B1 (en)	1999-12-15	2001-11-06	Allergan Sales, Inc.	Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies
ATE385421T1 (de)	2000-01-21	2008-02-15	Novartis Pharma Gmbh	Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
US6613917B1 (en)	2000-03-23	2003-09-02	Allergan, Inc.	Amines substituted with a dihydronaphthalenyl, chromenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
TWI281911B (en)	2000-04-04	2007-06-01	Allergan Inc	Treatment of tumors with RARalpha selective retinoid compounds in combination with other anti-tumor agents
US6387951B1 (en)	2000-08-29	2002-05-14	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6313107B1 (en) *	2000-08-29	2001-11-06	Allergan Sales, Inc.	Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI
US6380256B1 (en)	2000-08-29	2002-04-30	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6252090B1 (en)	2000-08-29	2001-06-26	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6369225B1 (en)	2000-08-29	2002-04-09	Allergan Sales, Inc.	Compounds having activity as inhibitors of cytochrome P450RAI
US6740676B2 (en)	2002-03-19	2004-05-25	Allergan, Inc.	4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-benzoic and 2-[4-[(8-ethynyl, 8-vinyl or 8-ethynyl-methyl)-6-chromanoyl]-phenyl]-acetic acid, their esters and salts having cytochrome p450rai inhibitory activity
US6720423B2 (en)	2002-04-30	2004-04-13	Allergan, Inc.	Dihydrobenzofuran and dihydrobenzothiophene 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors
US6620963B1 (en)	2002-09-19	2003-09-16	Allergan, Inc.	TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
US6759547B1 (en)	2003-01-14	2004-07-06	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl 2,6-difluoroheptatrienoic acid derivatives having serum glucose reducing activity
US7019034B2 (en)	2003-01-28	2006-03-28	Allergan, Inc.	Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals
US6759546B1 (en)	2003-02-04	2004-07-06	Allergan, Inc.	3,5-di-iso-propyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6884820B2 (en)	2003-04-03	2005-04-26	Allergan, Inc.	5,6,7,8-tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity
US6734193B1 (en)	2003-06-03	2004-05-11	Allergan, Inc.	(1,2,3,4-tetrahydroquinolin-8-yl)-heptatrienoic acid derivatives having serum glucose reducing activity
US6936636B2 (en)	2003-06-26	2005-08-30	Allergan, Inc.	5-[phenyl-tetrahydronaphthalene-2-yl dihydronaphthalen-2-yl and heteroaryl-cyclopropyl]-pentadienoic acid derivatives having serum glucose reducing activity
US6887896B1 (en)	2003-10-29	2005-05-03	Allergan, Inc.	7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity
EP1701934B1 (fr)	2003-12-26	2009-02-25	Allergan, Inc.	OXIMES DE CHALCONE DISUBSTITUES AYANT UNE ACTIVITE ANTAGONISTE DU RECEPTEUR DES RETINOIDES RAR-(Gamma)
US7476673B2 (en)	2003-12-30	2009-01-13	Allergan, Inc.	Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
US20160263189A1 (en)	2013-10-23	2016-09-15	Acadia Pharmaceuticals Inc.	Treatment of a neurodegenerative disease or disorder
CN113302206A (zh)	2018-11-26	2021-08-24	戴纳立制药公司	治疗脂质代谢失调的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62215581A (ja) *	1986-03-18	1987-09-22	Koichi Shiyudo	フラボンカルボン酸誘導体
US4885311A (en) *	1987-06-29	1989-12-05	Molecular Design International	Topical transretinoids for treatment of acne and skin diseases
LU86969A1 (fr) *	1987-08-12	1989-03-08	Oreal	Association de derives de pyrimidine et de retinoides en composants separes pour induire et stimuler la croissance des cheveux et diminuer leur chute
US4916250A (en) *	1988-10-31	1990-04-10	Loyola University Of Chicago	Phosphonate reagent compositions
FR2641184B1 (fr) *	1988-12-30	1991-04-05	Oreal	Composition pour induire et stimuler la croissance des cheveux et/ou freiner leur chute, a base de derives de pyrimidine et de filtres solaires
ES2022025A6 (es) *	1990-05-07	1991-11-16	Univ Valencia Estudi General	Procedimiento para la preparacion de acidos retinoicos y sus derivados.
JP2948923B2 (ja) *	1990-12-27	1999-09-13	日清製粉株式会社	レチノイン酸およびその異性体の製造方法
CZ282548B6 (cs)	1992-01-22	1997-08-13	F. Hoffmann-La Roche Ag	Farmaceutický přípravek

1992
- 1992-12-18 DE DE0617614T patent/DE617614T1/de active Pending
- 1992-12-18 JP JP51122193A patent/JP4001618B2/ja not_active Expired - Lifetime
- 1992-12-18 AU AU34218/93A patent/AU679171B2/en not_active Expired
- 1992-12-18 DE DE2001199015 patent/DE10199015I2/de active Active
- 1992-12-18 EP EP97105922A patent/EP0807624B1/fr not_active Revoked
- 1992-12-18 ES ES93902758T patent/ES2066750T3/es not_active Expired - Lifetime
- 1992-12-18 AT AT97105922T patent/ATE439341T1/de not_active IP Right Cessation
- 1992-12-18 CA CA002123223A patent/CA2123223C/fr not_active Expired - Lifetime
- 1992-12-18 DE DE69233768T patent/DE69233768D1/de not_active Revoked
- 1992-12-18 WO PCT/US1992/011214 patent/WO1993011755A1/fr not_active Ceased
- 1992-12-18 EP EP93902758A patent/EP0617614B1/fr not_active Expired - Lifetime
- 1992-12-18 AT AT93902758T patent/ATE163544T1/de active
- 1992-12-18 DE DE69224660T patent/DE69224660C5/de not_active Expired - Lifetime
- 1992-12-18 DK DK93902758T patent/DK0617614T3/da active
2001
- 2001-04-04 LU LU90752C patent/LU90752I2/fr unknown
- 2001-04-09 NL NL300043C patent/NL300043I2/nl unknown
2007
- 2007-05-07 JP JP2007122307A patent/JP2007254481A/ja active Pending

Also Published As

Publication number	Publication date
WO1993011755A1 (fr)	1993-06-24
DE10199015I2 (de)	2004-01-29
EP0807624A2 (fr)	1997-11-19
EP0617614B1 (fr)	1998-03-04
CA2123223C (fr)	2001-10-09
ES2066750T3 (es)	1998-07-01
DE617614T1 (de)	1995-06-08
AU3421893A (en)	1993-07-19
ES2066750T1 (es)	1995-03-16
DE69224660T2 (de)	1998-07-16
CA2123223A1 (fr)	1993-06-24
DE69233768D1 (de)	2009-09-24
NL300043I1 (nl)	2001-06-01
DE69224660D1 (de)	1998-04-09
ATE163544T1 (de)	1998-03-15
DE69224660C5 (de)	2010-06-02
DE10199015I1 (de)	2001-05-10
JP2007254481A (ja)	2007-10-04
NL300043I2 (nl)	2001-11-01
LU90752I2 (fr)	2001-06-05
EP0807624A3 (fr)	1999-09-29
AU679171B2 (en)	1997-06-26
ATE439341T1 (de)	2009-08-15
JPH08502238A (ja)	1996-03-12
JP4001618B2 (ja)	2007-10-31
EP0617614A1 (fr)	1994-10-05
EP0807624B1 (fr)	2009-08-12

Publication	Publication Date	Title
DE69233768D1 (de)	2009-09-24	Retinsäurederivate
KR960700215A (ko)	1996-01-19	레티노이드 X 수용체에 대한 선택성을 갖는 화합물(Compounds Having Selectivity for Retinoid X Receptors)
ES2149814T3 (es)	2000-11-16	Compuestos que tienen selectividad para los receptores de retinoides x.
MX9306627A (es)	1994-07-29	Compuestos que tienen actividad selectiva para losreceptores de los retinoides x y medios para modu lar los procesos mediados por los receptores de los retinoides x .
CA2075182A1 (fr)	1991-08-10	Compositions et methodes receptrices retinoides
ES2154398T3 (es)	2001-04-01	Piridinas 2,3-sustituidas para el tratamiento de la inflamacion.
FI844230A0 (fi)	1984-10-29	Enzyminhibition.
NO970580L (no)	1997-02-07	Retinsyre-X-reseptorligander
BR8406642A (pt)	1985-10-15	Bismaleimida,composicao de resina"prepregavel",prepreg e composto
DK0975359T3 (da)	2003-11-24	Anvendelse af forbindelser, der binder en cytoplasmisk dipeptidase til synergistisk virkning af immunreaktionen
EP0982988A4 (fr)	2000-04-05	Zonuline pratiquement pure, modulateur physiologique des jonctions serrees mammaliennes
DK0639275T3 (da)	1998-04-14	Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
ATE176668T1 (de)	1999-02-15	Neue 9-n-bicyclische nucleosidverbindungen nützlich als selektive inhibitoren von proinflammatorische cytokinen
BR9806811A (pt)	2000-05-16	Processo e aparelho para utilização no aperfeiçoamento da qualidade de tráfego de voz num sistema de telefonia.
MX9102347A (es)	1992-06-01	Composicion nematicida que contiene el compuesto 2r, 5r-dihidroximetil-3r,4r-dihidroxipirrolidina.
SE8404006D0 (sv)	1984-08-07	Aspartam-syntes
Clothier et al.	1990	Validation of alternative toxicity tests: principles, practices and cases
DK487287A (da)	1988-03-27	Antigestagener til haemning af den uterine prostagladinsyntese
FR2359451A1 (fr)	1978-02-17	Procede et dispositif pour la synchronisation du fonctionnement sequentiel d'appareils, notamment des feux de signalisation de circulation
ATE90338T1 (de)	1993-06-15	Verfahren zur herstellung von cypermethrinisomeren.
JPS5275225A (en)	1977-06-24	White color for developing system beam index type color television
JPS6432295A (en)	1989-02-02	Liquid crystal driving circuit
JPS5218337A (en)	1977-02-10	Optical unit
KR910011042A (ko)	1991-06-29	전원회로의 분주식 동기방법
JPS5272446A (en)	1977-06-16	Chopper type constant voltage power source system